西班牙裔男性局限性前列腺癌在就诊风险分组与治疗可及性方面的差异
基于美国国家癌症数据库2004—2017年895,087例局限性前列腺腺癌患者,按种族亚组与西班牙裔原籍国分层分析。西班牙裔男性较非西班牙裔白人男性就诊时更高风险分组的比值比AOR=1.18(95%CI 1.16-1.21,p<0.001);在不良风险疾病中西班牙裔男性接受治疗的比值比较非西班牙裔白人低(95%CI 0.57-0.67,p<0.001)。西班牙裔黑人患者接受治疗的比值是非西班牙裔黑人患者的2.00倍(95%CI 1.17-3.41,p=0.011)。
要点
- 西班牙裔男性就诊时更高风险局限性前列腺癌的比值高于非西班牙裔白人男性,AOR=1.18(95%CI 1.16-1.21,p<0.001)。
- 不良风险疾病中西班牙裔男性接受治疗的比值低于非西班牙裔白人男性(95%CI 0.57-0.67,p<0.001)。
- 按原籍国分层后差异持续存在,尤其在墨西哥男性中。
核心结论
- 按种族亚组与原籍国分层后,就诊风险分组与更高风险疾病治疗方面存在明显异质性。
- 作者认为研究结果支持在西班牙裔社区进一步收集分层数据并研究观察到的差异的潜在机制。
研究设计与样本
- 基于美国国家癌症数据库(NCDB)识别2004—2017年诊断的局限性前列腺腺癌患者,样本量n=895,087。
- 按种族亚组与西班牙裔原籍国进行分层。
- 采用有序逻辑回归定义就诊时风险分组逐步升高及不良风险疾病接受治疗的调整比值比(AOR)及95%CI。
主要发现
- 西班牙裔男性较非西班牙裔白人男性就诊时更高风险局限性前列腺癌的比值比AOR=1.18(95%CI 1.16-1.21,p<0.001)。
- 西班牙裔黑人男性较非西班牙裔黑人男性就诊时更高风险疾病的比值更低。
- 按原籍国分层后差异存在,尤其在墨西哥男性中。
- 不良风险疾病中西班牙裔男性接受治疗的比值较非西班牙裔白人男性低(95%CI 0.57-0.67,p<0.001)。
- 西班牙裔黑人患者接受治疗的比值是非西班牙裔黑人患者的2.00倍(95%CI 1.17-3.41,p=0.011)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite great heterogeneity amongst Hispanic groups, prostate cancer studies often report Hispanic patients in aggregate. We sought to identify differences in prostate cancer risk group at presentation and treatment status among Hispanic subgroup populations. METHODS: Patients with localized prostate adenocarcinoma diagnosed from 2004-2017 were identified in the National Cancer Database (NCDB) and disaggregated by racial subgroup and Hispanic country of origin. Ordinal logistic regression defined adjusted odds ratios (AORs) with 95% CI of (1) presenting at progressively higher risk group and (2) receiving treatment with intermediate-unfavorable or high-risk disease. RESULTS: In our sample (n = 895,087), Hispanic men had greater odds of presenting with higher-risk localized prostate cancer compared with non-Hispanic White men (AOR = 1.18 95% CI 1.16-1.21, p < 0.001). Additionally, Hispanic Black men were less likely to present with higher-risk disease than non-Hispanic Black men. Disparities also existed when disaggregated by country of origin, particularly for Mexican men. Amongst men with unfavorable-risk disease, Hispanic men were less likely to receive treatment than non-Hispanic White men (95% CI 0.57-0.67, p < 0.001). The odds of Hispanic Black patients receiving treatment was 2.00 times the odds (95% CI 1.17-3.41 p = 0.011) of non-Hispanic Black patients receiving treatment. Upon disaggregation by country of origin, disparities persisted, particularly for Mexican men. CONCLUSION: We found marked heterogeneity when risk group at presentation and treatment for higher-risk disease were disaggregated by racial subgroup and country of origin. Our findings support further collection of disaggregated data in Hispanic communities and study of potential mechanisms underlying the observed differences.
引用
- Swami N, Baez YA, Franco I, et al. Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men. Prostate Cancer Prostatic Dis. 2022. PMID: 35306541. doi:10.1038/s41391-022-00526-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。